JP2022553934A5 - - Google Patents
Info
- Publication number
- JP2022553934A5 JP2022553934A5 JP2022522825A JP2022522825A JP2022553934A5 JP 2022553934 A5 JP2022553934 A5 JP 2022553934A5 JP 2022522825 A JP2022522825 A JP 2022522825A JP 2022522825 A JP2022522825 A JP 2022522825A JP 2022553934 A5 JP2022553934 A5 JP 2022553934A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- particle size
- compound
- size distribution
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923290P | 2019-10-18 | 2019-10-18 | |
| US62/923,290 | 2019-10-18 | ||
| PCT/US2020/056027 WO2021076922A1 (en) | 2019-10-18 | 2020-10-16 | Pharmaceutical formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553934A JP2022553934A (ja) | 2022-12-27 |
| JP2022553934A5 true JP2022553934A5 (cg-RX-API-DMAC10.html) | 2023-10-24 |
Family
ID=75492817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522825A Pending JP2022553934A (ja) | 2019-10-18 | 2020-10-16 | 薬学的製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210114973A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4045480A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022553934A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240039083A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117597327A (cg-RX-API-DMAC10.html) |
| AR (1) | AR122323A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3157861A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW202128610A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021076922A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2661000T3 (es) | 2014-09-12 | 2018-03-27 | Antibiotx A/S | Uso antibacteriano de salicilanilidas halogenadas |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| UA125747C2 (uk) | 2015-09-01 | 2022-06-01 | Фьост Вейв Байо, Інк. | Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| WO2021174024A1 (en) * | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| US11045434B1 (en) | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| JP2024524414A (ja) * | 2021-07-02 | 2024-07-05 | キョンボ ファーム カンパニー リミテッド | ５－ヒドロキシ－１－メチルイミダゾリジン－２，４－ジオン化合物を有効成分として含む動物用薬学的組成物 |
| CN113768937B (zh) * | 2021-11-15 | 2022-04-08 | 恒翼生物医药科技(上海)有限公司 | 用于降低尿酸水平的化合物 |
| GB202301306D0 (en) * | 2023-01-30 | 2023-03-15 | Ucl Business Ltd | Treatment of granulomatous disease |
| CN116377019A (zh) * | 2023-03-07 | 2023-07-04 | 浙江师范大学 | 基于fret和应激颗粒的病毒3c蛋白酶抑制剂双筛选方法 |
| CN117357523B (zh) * | 2023-10-25 | 2026-06-19 | 澳门大学 | 利拉萘酯在制备预防和治疗肺纤维化药物中的用途 |
| CN117466786A (zh) * | 2023-12-25 | 2024-01-30 | 湖南一格制药有限公司 | 盐酸戊乙奎醚杂质及其制备方法 |
| WO2025207484A1 (en) * | 2024-03-25 | 2025-10-02 | Merveille.Ai | Use of aprepitant and cyclic dipeptide for weight control |
| CN118649135B (zh) * | 2024-07-18 | 2024-12-10 | 广东药科大学 | 一种缓解高尿酸血症肾病进程的药物制剂及其制备方法 |
| CN119525016B (zh) * | 2024-12-24 | 2026-04-07 | 中国矿业大学 | 一种组合捕收剂及其在钾长石反浮选脱硅中的应用 |
| CN119431243B (zh) * | 2025-01-09 | 2025-06-10 | 万邦德制药集团有限公司 | 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用 |
| CN119841970B (zh) * | 2025-01-23 | 2026-02-27 | 集美大学 | 一种具有抗炎活性的乙酰化卡拉胶及其制备方法和应用 |
| CN121406752B (zh) * | 2025-12-26 | 2026-06-12 | 圣湘生物科技股份有限公司 | 粘性生物样本的液化组合产品、核酸检测试剂盒及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2557615C2 (de) * | 1975-12-20 | 1985-08-14 | Bayer Ag, 5090 Leverkusen | Neue Niclosamid-Suspensionsformulierungen |
| NZ223200A (en) * | 1988-01-15 | 1989-01-06 | Ancare Distributors | Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier |
| WO2004006906A2 (en) * | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| CN1546919A (zh) * | 2003-07-13 | 2004-11-17 | 叶声羽 | 桑拿浴房 |
| CN1626506A (zh) * | 2004-08-10 | 2005-06-15 | 李志良 | 高纯度、高收率氯硝柳胺的制备 |
| EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| CN103751854B (zh) * | 2014-01-20 | 2015-08-26 | 瞿介明 | 抗菌医用导管 |
| UA125747C2 (uk) * | 2015-09-01 | 2022-06-01 | Фьост Вейв Байо, Інк. | Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю |
| EP3168211A1 (en) * | 2015-11-10 | 2017-05-17 | Westfälische Wilhelms-Universität Münster | Pharmaceutical co-crystals of niclosamide |
-
2020
- 2020-04-07 US US16/842,695 patent/US20210114973A1/en not_active Abandoned
- 2020-10-16 TW TW109136022A patent/TW202128610A/zh unknown
- 2020-10-16 KR KR1020227016634A patent/KR20240039083A/ko not_active Ceased
- 2020-10-16 EP EP20877454.7A patent/EP4045480A4/en not_active Withdrawn
- 2020-10-16 CN CN202080088987.0A patent/CN117597327A/zh active Pending
- 2020-10-16 CA CA3157861A patent/CA3157861A1/en active Pending
- 2020-10-16 JP JP2022522825A patent/JP2022553934A/ja active Pending
- 2020-10-16 WO PCT/US2020/056027 patent/WO2021076922A1/en not_active Ceased
- 2020-10-19 AR ARP200102884A patent/AR122323A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230310595A1 (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| US12235270B2 (en) | Depleting tumor-specific tregs | |
| AU2013329083C1 (en) | Enhancement of the immune response | |
| ES2729961T3 (es) | Uso de antagonistas del receptor EP4 para su uso en el tratamiento de cáncer de hígado asociado a NASH | |
| Bellan et al. | Role of vitamin D in rheumatoid arthritis | |
| JP2018111700A (ja) | 急性骨髄性白血病（ａｍｌ）のための新規併用治療 | |
| CN108779091B (zh) | 色烯化合物和第二活性剂的组合 | |
| CA3107023A1 (en) | Ep4 inhibitors and synthesis thereof | |
| HK1251162A1 (en) | Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer | |
| CN115942977A (zh) | Cd73抑制剂的结晶形式及其用途 | |
| AU2014225373A1 (en) | Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis | |
| TW202515549A (zh) | 橋聯三環胺甲醯基吡啶酮化合物及其用途 | |
| TW202530226A (zh) | 橋聯三環胺甲醯基吡啶酮化合物及其用途 | |
| TW202530227A (zh) | 橋聯三環胺甲醯基吡啶酮化合物及其用途 | |
| CN115697317A (zh) | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 | |
| JP2022513072A5 (cg-RX-API-DMAC10.html) | ||
| Campbell et al. | P101 sarcopenia is associated with increased risk of infection in IBD patients older than 50 years starting biologic medications | |
| US20250177352A1 (en) | Combination treatment for cancer | |
| US20220184040A1 (en) | Method of treating malignant rhabdoid tumor of the ovary and small cell cancer of the ovary of the hypercalcemic type | |
| HK40086626A (en) | Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia | |
| HK1253277B (en) | Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer | |
| EA048934B1 (ru) | Способы лечения рака | |
| HK40065518A (en) | Method of treating malignant rhabdoid tumor of the ovary and small cell cancer of the ovary of the hypercalcemic type |